Retatrutide Dosage: What the Trials Reported

What doses of retatrutide were studied in the phase 2 trial?

In the phase 2 obesity trial, participants were assigned to maintenance doses of 1, 4, 8, or 12 mg of retatrutide once weekly, plus a placebo group (Jastreboff et al., 2023).

The trial (Jastreboff et al., New England Journal of Medicine 2023; doi:10.1056/NEJMoa2301972; PMID 37366315) enrolled 338 adults, ran for 48 weeks, and used gradual dose escalation to reach each assigned maintenance level. These are the exact arms the researchers tested, reported here for education only. They are not a schedule to follow.

The mg values are the maintenance targets, not starting points. The study built up to them over several weeks.

How was the retatrutide dosage escalated, and for how long?

Participants received retatrutide by subcutaneous injection once weekly for 48 weeks, with doses raised in steps to the assigned maintenance level (Jastreboff et al., 2023).

Slow escalation is common for GLP-1-class compounds because it tends to reduce early stomach-related side effects. In the trial this was part of a controlled protocol run under medical supervision. The 48-week window is the length of the reported data, not a promise about any timeline for a reader.

Is retatrutide an approved medication with an official dose?

No. Retatrutide is investigational, has no regulatory approval, and has no approved or prescribed dose, so the only figures that exist come from clinical trials (Jastreboff et al., 2023).

Phase 2 means the compound was tested for dose-finding and early safety in a limited group, not confirmed in the larger phase 3 studies that support approval. Because it is not a prescription product, there is no label, no approved indication, and no standard dose. Material sold for research is not intended for human use. Treat the trial arms above as data points, not instructions.

What is retatrutide, and how does it differ from other GLP-1 peptides?

Retatrutide is a triple receptor agonist, meaning one molecule acts on GIP, GLP-1, and glucagon receptors, while semaglutide targets GLP-1 alone and tirzepatide targets GIP and GLP-1 (Jastreboff et al., 2023; Jastreboff et al., 2022; Wilding et al., 2021).

The added glucagon-receptor activity is the main structural difference from the earlier compounds. The table below places the reported peak weight-loss numbers side by side for context. The added population and design column is a caveat: these figures come from separate programs with different enrollment criteria and trial lengths, so they are not interchangeable.

Footnote: These trials used different designs, durations, and populations (some enrolled overweight participants with comorbidity, others enrolled obesity only), so the numbers are not a direct head-to-head result. They show the range each program reported, not a ranking.

How did higher doses compare with lower doses?

The trial reported a dose-dependent pattern: the 8 and 12 mg arms produced greater mean weight loss than the 1 mg arm and placebo, with the 12 mg arm reaching up to about 24.2 percent at 48 weeks (Jastreboff et al., 2023).

Larger reductions at higher arms came alongside more frequent side effects, which is a common trade-off for this drug class. The 48-week figures are what the study measured, not a projection of what continues afterward.

What side effects were reported at these doses?

Gastrointestinal events such as nausea, diarrhea, and vomiting were the most commonly reported adverse events, and they appeared more often at the higher doses (Jastreboff et al., 2023).

Gradual escalation was used to soften these effects. Because retatrutide is still investigational, its full long-term safety profile is not yet established. This is one reason any use question routes to a licensed clinician rather than a self-guided plan.

What happens to weight after stopping a GLP-1-class compound?

Research on related GLP-1-class drugs reports that stopping treatment is commonly followed by weight regain, so trial weight change is tied to continued use under study conditions (Wilding et al., 2022; Aronne et al., 2024).

After semaglutide was stopped, participants regained about two-thirds of their lost weight one year later (Wilding et al., 2022). A similar regain pattern appeared after tirzepatide withdrawal (Aronne et al., 2024). A 2026 systematic review and nonlinear meta-regression across GLP-1 receptor agonists reported that regain after stopping tends to slow and plateau over time rather than climb in a straight line, with about 60 percent of the lost weight regained by one year and an estimated plateau near 75 percent of the weight lost on treatment (Budini et al., 2026). Part of this reflects the body's adaptive drop in energy expenditure after weight loss (Rosenbaum and Leibel, 2010). For retatrutide specifically, long-term and post-withdrawal human data are limited, so this context extrapolates from its drug class.

Who should decide a retatrutide dose?

A qualified clinician, not a web page: because retatrutide is investigational, any decision about use belongs to a licensed medical professional who can weigh individual risk.

The trial arms above describe what researchers studied. They do not tell any one person what is safe or appropriate for them. Individual factors, other medications, and health history all change the picture, and only a clinician can account for those.